Sagent Pharmaceuticals Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
Sagent Pharmaceuticals (SGNT) Posts Q1 GAAP Loss of 6c/Share
May 5, 2015 9:17 AM EDTSagent Pharmaceuticals (NASDAQ: SGNT) reported Q1 EPS of ($0.06), $0.10 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $82.6 million versus the consensus estimate of $80.63 million.
Sagent Pharmaceuticals sees FY2015 revenue of $325-375 million, versus the consensus of $345.8 million.
For earnings... More



